Skip to main content

Advertisement

SpringerLink
Log in

Platelet count: association with prognosis in lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Lung cancer (LC) is now the leading cause of cancer mortality in the world, therefore it would be useful to identify prognostic factors to determine patient outcome. The objective of this study is to evaluate the usefulness of platelet counts at the time of diagnosis as a prognostic factor. A retrospective study of patients with histological diagnostic evidence of LC was carried in our catchment area over a 3-year period. Survival adjusted for other factors was assessed according to the platelet count at the time of diagnosis. Patients with platelet levels within the reference range (RR) (135000–381000/µl) were divided into two groups, between 135000–258000/µl and 258000–381000/µl. A third group was made up of patients with platelet counts over 381000/µl. Adjusted survival was analysed using Cox regression models. Patients with high platelets have a 37% worse survival than those with a platelet level within the RR, but lower than 258000/µl. When tumour stage is included in the covariates, platelet levels are no longer an independent survival factor. In conclusion, platelet levels at the time of diagnosis could be a useful prognostic factor in LC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55(2):74–108. doi:10.3322/canjclin.55.2.74.

    Article  PubMed  Google Scholar 

  2. Alberg AJ, Ford JG, Samet JM, American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest. 2007;132(3 Suppl):29S–55S. doi:10.1378/chest.07-1347.

    Article  CAS  PubMed  Google Scholar 

  3. Black WC. Computed tomography screening for lung cancer: review of screening principles and update on current status. Cancer. 2007;16 [Epub ahead of print].

  4. Berghmans T, Lafitte JJ, Thiriaux J, VanHoutte P, Lecomte J, Efremidis A, et al. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer. 2004;45(3):339–48.

    Article  CAS  PubMed  Google Scholar 

  5. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9(9):1826–30. doi:10.1183/09031936.96.09091826.

    Article  CAS  PubMed  Google Scholar 

  6. Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, Tanaka M, et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration. 2004;71(2):170–3. doi:10.1159/000076679.

    Article  PubMed  Google Scholar 

  7. Watine J, Friedberg B, Charet JC. Laboratory variables and stratification of small-cell lung cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Ann Biol Clin (Paris). 2004;62(2):189–96.

    CAS  Google Scholar 

  8. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123–9. doi:10.1200/JCO.2005.03.133.

    Article  CAS  PubMed  Google Scholar 

  9. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130–5. doi:10.1200/JCO.2005.03.134.

    Article  CAS  PubMed  Google Scholar 

  10. World Health Organization. The World Health Organization histological typing of lung tumors (2nd ed.). Am J Clin Pathol. 1982;77:123–36.

    Google Scholar 

  11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. doi:10.1016/0021-9681(87)90171-8.

    Article  CAS  PubMed  Google Scholar 

  12. Costantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990;64(4):501–5.

    CAS  PubMed  Google Scholar 

  13. Iwasaki A, Hamanaka W, Harnada T, Maekawa S, Enatsu S, Shirakusa T. Significance of platelet counts in patients who underwent surgical treatment for lung metastasis. Int Surg. 2007;92(2):103–9.

    PubMed  Google Scholar 

  14. Segal JB, Moliterno AR. Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol. 2006;16(2):123–30. doi:10.1016/j.annepidem.2005.06.052.

    Article  PubMed  Google Scholar 

  15. Alexandrakis MG, Passam FH, Perisinakis K, Ganotakis E, Margantinis G, Kyriakou DS, et al. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med. 2002;96(8):553–8. doi:10.1053/rmed.2002.1328.

    Article  CAS  PubMed  Google Scholar 

  16. Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, et al. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res. 1993;207(2):332–9. doi:10.1006/excr.1993.1200.

    Article  CAS  PubMed  Google Scholar 

  17. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720–5. doi:10.1182/blood.V98.9.2720.

    Article  CAS  PubMed  Google Scholar 

  18. Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(1):25–31. doi:10.1158/1055-9965.EPI-05-0537.

    Article  PubMed  Google Scholar 

  19. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379–92. doi:10.1056/NEJMra035536.

    Article  CAS  PubMed  Google Scholar 

  20. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822–9. doi:10.1002/cncr.21496.

    Article  PubMed  Google Scholar 

  21. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2(12):2156–61. doi:10.1111/j.1538-7836.2004.00991.x.

    Article  CAS  PubMed  Google Scholar 

  22. Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol. 2006;8(1):1–5. doi:10.1016/j.amjcard.2006.01.046.

    Article  Google Scholar 

  23. Akiyama S, Furukawa T, Sumizawa T, Takebayashi Y, Nakajima Y, Shimaoka S, et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci. 2004;95(11):851–7. doi:10.1111/j.1349-7006.2004.tb02193.x.

    Article  CAS  PubMed  Google Scholar 

  24. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–7. doi:10.1038/nature04186.

    Article  CAS  PubMed  Google Scholar 

  25. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat. 1998;52(1–3):159–73. doi:10.1023/A:1006175504673.

    Article  CAS  PubMed  Google Scholar 

  26. Jurasz P, Alonso D, Castro-Blanco S, Murad F, Radomski MW. Generation and role of angiostatin in human platelets. Blood. 2003;102(9):3217–23. doi:10.1182/blood-2003-02-0378.

    Article  CAS  PubMed  Google Scholar 

  27. Ilhan N, Ilhan N, Deveci F. Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem. 2004;37(9):840–5. doi:10.1016/j.clinbiochem.2004.03.012.

    Article  CAS  PubMed  Google Scholar 

  28. Walz DA. Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer Metastasis Rev. 1992;11(3–4):313–24. doi:10.1007/BF01307185.

    Article  CAS  PubMed  Google Scholar 

  29. Yahalom J, Eldor A, Biran S, Fuks Z, Vlodavsky I. Platelet-tumor cell interaction with the subendothelial extracellular matrix: relationship to cancer metastasis. Radiother Oncol. 1985;3(3):211–25. doi:10.1016/S0167-8140(85)80030-X.

    Article  CAS  PubMed  Google Scholar 

  30. Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007;43(3):283–8. doi:10.1016/j.oraloncology.2006.03.010.

    Article  CAS  PubMed  Google Scholar 

  31. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198(5):737–41. doi:10.1016/j.jamcollsurg.2004.01.022.

    Article  PubMed  Google Scholar 

  32. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg. 2004;25(3):443–8. doi:10.1016/j.ejcts.2003.11.031.

    Article  PubMed  Google Scholar 

  33. Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, Vassy R, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer. 2007;58(2):205–13. doi:10.1016/j.lungcan.2007.06.021.

    Article  PubMed  Google Scholar 

  34. Cao Y. Direct role of PDGF-BB in lymphangiogenesis and lymphatic metastasis. Cell Cycle. 2005;4(2):228–30.

    CAS  PubMed  Google Scholar 

  35. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res. 2004;94(5):644–70. doi:10.1161/01.RES.0000118600.91698.BB.

    Article  Google Scholar 

  36. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005;65(11):4739–46. doi:10.1158/0008-5472.CAN-04-4576.

    Article  CAS  PubMed  Google Scholar 

  37. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006;66(5):2650–7. doi:10.1158/0008-5472.CAN-05-1843.

    Article  CAS  PubMed  Google Scholar 

  38. Guddo F, Fontanini G, Reina C, Vignola AM, Angeletti A, Bonsignore G. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol. 1999;30(7):788–94. doi:10.1016/S0046-8177(99)90139-9.

    Article  CAS  PubMed  Google Scholar 

  39. Brattström D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res. 1998;18(2A):1123–7.

    PubMed  Google Scholar 

  40. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178–85. doi:10.1182/blood-2004-06-2272.

    Article  CAS  PubMed  Google Scholar 

  41. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59(6):1295–300.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Neumoloxía-Complexo Hospitalario Clinico Universitario de Pontevedra, C/Choupana SN, 15706, A Coruña, Teo, Spain

    Francisco Javier Gonzalez Barcala

  2. Servicio de Cirurxia Toracica-Complexo Hospitalario Clinico Universitario de Santiago, A Coruña, Spain

    Jose Maria Garcia Prim & Milagros Moldes Rodriguez

  3. Atencion Primaria, A Coruña, Spain

    Julio Alvarez Fernandez & Maria Jose Rey Rey

  4. Servicio de Medicina Interna-Complexo Hospitalario Clinico Universitario de Santiago, Santiago de Compostela, Spain

    Antonio Pose Reino

  5. Servicio de Neumoloxía-Complexo Hospitalario Clinico Universitario de Santiago, Santiago de Compostela, Spain

    Luis Valdes Cuadrado

Authors
  1. Francisco Javier Gonzalez Barcala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose Maria Garcia Prim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Milagros Moldes Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julio Alvarez Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Jose Rey Rey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antonio Pose Reino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luis Valdes Cuadrado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco Javier Gonzalez Barcala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gonzalez Barcala, F.J., Garcia Prim, J.M., Moldes Rodriguez, M. et al. Platelet count: association with prognosis in lung cancer. Med Oncol 27, 357–362 (2010). https://doi.org/10.1007/s12032-009-9217-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9217-9

Keywords

Search

Navigation